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Introduction: The use of multi-parametric (MP) MRI to diagnose prostate cancer has 
been the subject of intense research, with many studies showing positive results. The 
purpose of our study is to better understand the accessibility, role, and perceived accu-
racy of MP-MRI in practice by surveying practicing urologists.
Materials and Methods: Surveys were sent to 7,400 practicing American Urological 
Association member physicians with a current email address. The survey asked demo-
graphic information and addressed access, accuracy, cost, and role of prostate MRI in 
clinical practice.
Results: Our survey elicited 276 responses. Respondents felt that limited access and 
prohibitive cost of MP-MRI limits its use, 72% and 59% respectively. Academic uro-
logists ordered more MP-MRI studies per year than those in private practice (43.3% 
vs. 21.1%; p<0.001). Urologists who performed more than 30 prostatectomies a year 
were more likely to feel that an MP-MRI would change their surgical approach (37.5% 
vs. 19.6%, p-value=0.002). Only 25% of respondents agreed or strongly agreed that 
MP-MRI should be used in active surveillance. For patients with negative biopsies and 
elevated PSA, 39% reported MP-MRI to be very useful.
Conclusions: Our study found that MP-MRI use is most prominent among practitioners 
who are oncology fellowship-trained, practice at academic centers, and perform more 
than 30 prostatectomies per year. Limited access and prohibitive cost of MP-MRI may 
limit its utility in practice. Additionally, study participants perceive a lack of accuracy 
of MP-MRI, which is contrary to the recent literature.
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InTRODuCTIOn
Prostate cancer is the second leading cause 
of cancer-related death in men, claiming almost 
30.000 lives in 2013 (1). It is a heterogeneous di-
sease with differences in biological aggressive-
ness, and the natural history of prostate cancer 
is highly variable from patient to patient. It has 
been shown that over half of those diagnosed with 
prostate cancer will die of other causes (2). In li-
ght of the United Service Preventative Task Force 
recommendation against the use of prostate speci-
fic antigen (PSA) for cancer screening, as well as 
several studies demonstrating no survival advan-
tage with aggressive treatment, there has been a 
growing interest in the use of active surveillance 
in prostate cancer management (3). As the treat-
ment algorithm for prostate cancer continues to 
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evolve, there has been increased emphasis on the 
use of multi-parametric magnetic resonance ima-
ging (MP-MRI) to aid in the diagnosis and mana-
gement of prostate cancer, especially within the 
active surveillance population.
MRI provides high-resolution anatomic de-
tail via T2 weighted images and allows for functio-
nal assessment of the prostate. Dynamic contrast 
enhanced imaging measures the vascularity of tu-
mors, and the vascular nature of prostate cancer 
shows both increased uptake and washout of gado-
linium contrast when given intravenously (4). Di-
ffusion weighted imagining measures the diffusion 
of water through tissue, causing prostate cancer 
to exhibits reduced diffusion compared to normal 
prostate tissue due to its densely packed cells.
Despite demonstration of the benefit wi-
thin the literature, MP-MRI has been slow to gain 
widespread acceptance (5). The practice patterns, 
experience, and attitudes of American urologists 
regarding the use of MRI in the management of 
prostate cancer have not been previously exami-
ned. The goal of our study is to characterize the 
opinions amongst current American urologists 
concerning the role of MP-MRI in prostate cancer 
management.
MATERIALs AnD METhODs
This study was reviewed and approved by 
the Institution Review Board at Washington Univer-
sity. A web-based survey consisting of twenty ques-
tions was developed and sent electronically to 7,400 
current American Urological Association (AUA) 
members. All survey participants were practicing 
urologic physicians in the United States had current 
email addresses as of September 01, 2013. An initial 
email with a brief explanation of the study and an 
invitation to complete the survey was sent on Sep-
tember 12, 2013, and a reminder email for those who 
had yet to complete the survey was sent on Sep-
tember 25, 2013. Respondents were not required to 
answer all questions for submission of their survey. 
Each email was embedded with a personalized link 
to ensure that each respondent could only submit a 
single survey, and all responses were confidential.
Each survey was de-identified and respon-
ses were collected using our institutional RedCap 
electronic data-capturing tool (6). Survey ques-
tions addressing practitioner demographics inclu-
ded: how many years since finishing residency, 
post-residency training, proximity to nearest ter-
tiary care center, structure of medical practice, 
practice setting, and number of prostatectomies 
performed yearly. Questions addressing practitio-
ner opinion of MP-MRI included: evidence in lite-
rature supporting MP-MRI, reliability of the results 
of MP-MRI, and accuracy of MP-MRI measured by 
correlation between MP-MRI results and positive 
biopsies/final pathology after prostatectomy.
Categorical responses to survey questions 
were assessed using Chi-square test of indepen-
dence analysis and Fisher’s exact test. Continuous 
variables were compared with the Student’s t-test, 
and statistical analyses were two-sided using a 
significance of 0.05.
REsuLTs
Our survey elicited 276 (3.8%) responses 
from practicing AUA member physicians. Unfortu-
nately, not all participants answered every survey 
question. The demographics that were obtained 
from the survey question can be found in Table-1. 
Overall, a majority of survey participants reported 
ordering 1-10 MP-MRIs a year to evaluate prostate 
cancer. Forty-two percent of respondents agreed 
that there was adequate evidence within the lite-
rature supporting the use of MP-MRI in localized 
prostate cancer (114/272), 31% disagreed (84/272), 
and 27% could not decide (74/272). A summary of 
survey responses can be found in Table-2.
Access
When respondents were stratified by 
their type of practice, there was a statistically 
significant increase in the reported number of 
MP-MRIs ordered by physicians who practice in 
an academic setting compared those who do not 
(>11 MP-MRIs/year, 43% versus 21% p=0.0001). 
Eighty-nine percent of respondents endorsed 
having local access (less than 1hr) to facilities with 
MP-MRI capabilities (245/276). However, when all 
respondents were asked if they felt that access to 
qualified imaging centers and radiologists limited 
their use of MP-MRI, 72% of respondents agreed or 
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strongly agreed (192/268). When asked if the cost 
of MP-MRI was prohibitive for its use, 59% of all 
respondents agreed or strongly agreed (156/263).
Role of MRI
Overall, 34% of respondents reported using 
MP-MRI targeted biopsies, either ultrasound fu-
Table 1 - survey Demographics.
How many years since you finished residency? Total = 276
0-5 years 54 (19.5%)
6-10 years 39 (14.1%)
11-20 years 77 (27.8%)
21-30 years 77 (27.8%)
Over 31 years 29 (10.5%)
What training, if any, did you complete after residency? Total = 274
None 159 (58%)
Minimal Invasive/Endourology Fellowship 21 (7.7%)
Oncology Fellowship 66 (24.1%)
Reconstructive Fellowship 9 (3.3%)
Other 19 (6.9%)
Approximately how close is the nearest tertiary care center to your practice? Total = 276
I primarily practice at a tertiary care center 134 (48.6%)
Less than 1 hour 95 (34.4%)
Less than 2 hours 32 (11.6%)
Less than 3 hours 5 (1.8%)
More than 3 hours 10 (3.6%)
What type of practice do you work in primarily? Total = 276
Private Group or Solo 164 (59.2%)
Academic 91 (32.9%)
Government (VA, Military service, National Health Service) 7 (2.5%)
Other 15 (5.4%)
What type of setting do you practice in? Total = 276
Urban 151 (54.7%)
Suburban 103 (37.2%)
Rural 22 (8%)
On average, how many prostatectomies do you preform yearly for Prostate cancer? Total = 275
Under 10 105 (38.2%)
30-Oct 85 (30.9%)
30-100 71 (25.8%)
Over 100 14 (5.1%)
sion or cognitive techniques (91/270). When these 
responses were stratified by fellowship training, 
we found that respondents with oncology fello-
wship training performed significantly more MP-
-MRI targeted biopsies compared to those who did 
not (44.6% versus 30.1%, p=0.032). In our sur-
vey, 38% of all respondents found MP-MRI to be 
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Table 2 - survey Responses.
There is adequate evidence supporting the use of MP-MRI to manage localized prostate cancer. Total = 272
Agree 114 (42%)
Disagree 84 (31%)
Can not decide 74 (27%)
Access to MP-MRI limits my ability to use it in my practice. Total = 268
Agree/Strongly agree 192 (72%)
Disagree/Strongly disagree 76 (28%)
The high cost of MP-MRI is prohibitive for its use. Total = 263
Agree/Strongly agree 156 (59%)
Disagree/Strongly disagree 107 (41%)
MR-MPI guided biopsies are utilized in my practice. Total = 270
Agree 91 (34%)
Disagree 179 (66%)
MP-MRI is helpful in patients with elevated PSA/abnormal prostate exam prior to biopsy. Total = 270
Agree/Strongly agree 102 (38%)
Disagree/Strongly disagree 168 (62%)
MP-MRI is helpful in patients with negative biopsy and abnormal PSA/prostate exam. Total = 225
Agree/Strongly agree 88 (39%)
Disagree/Strongly disagree 137 (61%)
MP-MRI is useful prior to definitive treatment with prostatectomy or radiation. Total = 225
Agree/Strongly agree 32 (14%)
Disagree/Strongly disagree 193 (86%)
MP-MRI changes my treatment approach of intermediate/high risk prostate cancer. Total = 253
Sometimes/often 66 (26%)
Rarely/never 187 (74%)
MP-MRI should be used in all patients for active surveillance. Total = 276
Agree/Strongly agree 69 (25%)
Disagree/Strongly disagree 207 (75%)
How often do MP-MRI guided biopsies turn out to be positive? Total = 233
Often/Very often 65 (28%)
Sometimes 77 (33%)
Rarely/Never 91 (39%)
How closely do MP-MRI results correlate with final pathology after prostatectomy? Total = 233
Strong correlation 26 (11%)
Moderate correlation 145 (62%)
Weak correlation 46 (20%)
No correlation 16 (7%)
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helpful in a patient with an elevated PSA or ab-
normal prostate exam prior to biopsy (102/270). 
When these responses where stratified by fello-
wship training, we found 48.2% of respondents 
with oncology training found MP-MRI somewhat 
or very helpful in this situation compared to 
33.5% of respondents without oncology training. 
This difference was found to be trending towards 
significance with a p value of 0.057.
In patients with a negative biopsy and an 
elevated PSA/abnormal prostate exam, 39% of all 
respondents reported MP-MRI to be very helpful 
(88/225). Fourteen percent of respondents repor-
ted MP-MRI to be very useful when utilized prior 
to definitive treatment with either prostatectomy 
or radiation (32/225). In patients with intermedia-
te or high risk prostate cancer who appear to be 
candidates for a nerve sparing prostatectomy, 26% 
of respondents report that getting an MP-MRI will 
sometimes or often change their surgical approa-
ch to a non-nerve sparing prostatectomy (66/253). 
When stratified based on average number of pros-
tatectomies performed per year (<30 versus >30); 
we found that surgeons who perform more than 
30 prostatectomies per year are more likely to 
change their surgical approach based on MP-MRI 
than those who perform less than 30/year (37% 
versus 20%, p=0.002).
Regarding the use of MP-MRI in active 
surveillance, 25% of all respondents agreed that 
it should be used in all patients (69/276). When 
asked if MP-MRI should be used to evaluate pa-
tients for active surveillance, 30.7% of respon-
dents who were 10 years or less out of residency 
reported MP-MRI to be very helpful compared to 
24.8% of respondents 11 years or more out of re-
sidency (30/98 versus 45/183).
Accuracy
When asked approximately what propor-
tion of patients with positive MP-MRI findin-
gs who subsequently undergo MP-MRI targeted 
prostate biopsies are found to have biopsies po-
sitive for prostate cancer, 28% reported positive 
biopsies “often” or “very often” (65/233), 33% re-
ported positive biopsies “sometimes” (77/233), and 
39% reported positive biopsies “rarely” or “never” 
(91/233). Similarly, when asked about how closely 
respondents find MP-MRI results to correlate with 
final pathology after prostatectomy, 11% reported 
strong correlation (26/233), 62% reported mo-
derate correlation (145/233), 20% reported weak 
correlation (46/233), and 7% reported no correla-
tion (16/233).
DIsCussIOn
The use of multi-parametric (MP-MRI) to 
diagnose prostate cancer has been the subject of 
intense research, with many studies showing po-
sitive results. To our knowledge, no other studies 
have attempted to better understand the acces-
sibility, role, and perceived accuracy of MP-MRI 
in practice by surveying practicing urologists. 
We found practicing in an academic center to be 
strongly associated with increased use of MP-MRI 
(p=0.0001), which is likely due to a combination 
of increased access, familiarly with recent litera-
ture, and interdisciplinary efforts within academic 
institutions.
Access
There is very little within the literature 
evaluating practitioner access to MP-MRI, parti-
cularly outside academic centers. While 89% of 
our respondents reported to be within one hour 
of a facility with MP-MRI capabilities, 72% still 
felt that their use of MP-MRI was limited by lack 
of access. While the exact reasons for this discre-
pancy could not be gleaned from the survey data, 
causes may relate to perceived lack of quality 
in the MP-MRI provided, difficulty with patient 
scheduling, or lack of strong multi-disciplinary 
relationship with radiologists.
Another possible reason that MP-MRI has 
been slow to gain wide spread popularity is that 
many (59% within our study) feel that the cost of 
these studies is prohibitive, and that issues sur-
rounding insurance reimbursement negate the 
perceived value of the study. As the presence of 
MP-MRI becomes stronger in national and inter-
national management guidelines, insurance ap-
proval and payment for these studies may become 
more streamlined (7-9). Likewise, as the guidelines 
for active surveillance continue to evolve, MP-
-MRI may be incorporated into these algorithms, 
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which will support this study as a reimbursable 
indication.
Role
The use of MP-MRI in the management 
of prostate cancer has gained a lot of attention 
in recent literature; however, the appropriate 
use in clinical practice has not yet been establi-
shed. Despite the growing body of evidence su-
pporting the use of MP-MRI guided biopsies in 
lieu of saturation biopsies, many of our respon-
dents did not echo this sediment. We found that 
only 42% of respondents felt that the current 
literature provided evidence for some role for 
MP-MRI in localized prostate cancer patients, 
while 31% disagreed and 27% could not decide. 
These results further prove the level of contro-
versy surrounding MP-MRI.
MP-MRI can be used to provide guidan-
ce for tissue sampling either directly, via a cog-
nitive approach, or through fusion software. MP-
-MRI guided biopsies have been shown to upgrade 
Gleason grade and detect otherwise undiagnosed 
anterior gland tumors in a significant number of 
patients (10-13). Despite this, only 34% of respon-
dents reported using MP-MRI guided biopsies in 
their clinical practice. However, level of training 
was found to be associated with an increased use 
of MP-MRI guided biopsies. Completion of an on-
cology fellowship resulted in statistically signifi-
cant increases in usage (p=0.032), and completion 
of any urologic fellowship also trended towards 
a significant increase (p=0.057). While this may 
be in part due to the fact that many of these uro-
logists practice at academic centers, these results 
suggest that further training and education on 
MP-MRI guided biopsies may be useful to guide 
practice.
In intermediate or high-risk prostate can-
cer patients who appear to be candidates for a ner-
ve sparing prostatectomy, MP-MRI can be helpful 
for surgical planning (14-15). Of our respondents, 
38% found MP-MRI to be helpful when used in this 
capacity. We also found those urologists who re-
ported doing more than 30 prostatectomies a year 
used MP-MRI for surgical or treatment planning 
at a higher frequency compared to their collea-
gues (p=0.002). It is possible that urologists with 
more operative experience may have increased 
expertise and familiarity with MP-MRI. It is also 
possible that they handle more complex cases, re-
quiring the use of additional imaging modalities.
It has also been proposed to incorporate 
MP-MRI into active surveillance protocols (16-17). 
While the majority of current evidence suggests a 
benefit to its incorporation, there have been some 
studies that failed to demonstrate an improvement 
in the stratification of patients (18-19). In our stu-
dy, only 25% of all respondents agreed or strongly 
agreed that MP-MRI should be used in all patients 
on active surveillance. In patients with a previous 
negative biopsy and a rising PSA or abnormal DRE 
there are several studies that have found MP-MRI 
to be helpful and this has been incorporated in to 
many current guidelines (7-9, 20-21). Despite this, 
only 39% of respondents in our study agreed that 
MP-MRI was helpful or very helpful for these pa-
tients. Reasons for this disconnect may be related 
to the dissemination of this information to practi-
cing urologists or perceived poor performance of 
MRI in practice.
Accuracy
While several studies have shown the high 
accuracy of MP-MRI, respondents seemed to lar-
gely express skepticism (13, 22-23). There were 
a large proportion of respondents who felt that 
MP-MRI was relatively inaccurate, with moderate-
-poor correlation with pathology and little posi-
tive impact on patient care. While the reason for 
these opinions was not elucidated in our study, 
this negative impression of MP-MRI may reflect 
differences in local radiologist and pathologist 
ability to interpret and correlate MP-MRI findings. 
It is well accepted that achieving accurate radiolo-
gy-pathology correlation with MP-MRI findings is 
challenging, and it has been suggested that stan-
dardization of protocols is the best way to overco-
me these challenges (24-25). The European Society 
for Urogenital Radiology has developed guidelines 
to standardize reporting and acquisition of pros-
tate MRIs, named the Prostate Imaging Reporting 
and Diagnostic System (PI-RADS) (8). Unfortuna-
tely, this system has not been universally adop-
ted in the United States. Further standardization 
may help to ensure that the use of MP-MRI in the 
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community mirrors the same accuracy and pro-
vides the same patient benefits as those reported 
in the literature. As urologists are able to master 
this learning curve, one would expect accuracy to 
improve.
There are several limitations to our stu-
dy. The response rate of only 3.8% is clearly less 
than ideal, and it would have been preferable if all 
respondents had answered every survey question. 
Never the less, with 276 respondents exhibiting 
a wide range of demographics, we feel that the 
responses provide an adequate sample size. The 
survey was designed to provide data that could be 
easily analyzed, yet multiple choice answers carry 
the risk of being leading. It might be anticipated 
that the survey would have promoted a bias to-
ward MP-MRI, yet the results indicate otherwise. 
Further directions for research include a survey 
administered to a large number of practitioners 
across different vendor platforms and in various 
institutional settings. Also, it would be helpful to 
obtain insight into why practitioners chose their 
various answers, would could be accomplished 
with a more in-depth amended to include the op-
tion for free response.
COnCLusIOn
Prostate MRI has been shown within the li-
terature to be a highly useful diagnostic tool. Ho-
wever, our study indicates a relatively low level of 
support for the use of MP-MRI in clinical practice. 
This indicates the need for improved education, 
access, and standardization of treatment recom-
mendations to address the challenges of imple-
menting this new technology into practice. Further 
research is needed to confirm the favorable results 
of MP-MRI across different vendor platforms, in 
various institutional settings, and using available 
radiologic-pathologic correlation.
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